Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50 - Reck, M; Rodriguez-Abreu, D; Robinson, AG (J Clin Oncol, 2021)